Sánchez-Bilbao, L.; Martínez-López, D.; Revenga, M.; López-Vázquez, Á.; Valls-Pascual, E.; Atienza-Mateo, B.; Valls-Espinosa, B.; Maiz-Alonso, O.; Blanco, A.; Torre-Salaberri, I.;
et al. Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients. J. Clin. Med. 2020, 9, 2816.
https://doi.org/10.3390/jcm9092816
AMA Style
Sánchez-Bilbao L, Martínez-López D, Revenga M, López-Vázquez Á, Valls-Pascual E, Atienza-Mateo B, Valls-Espinosa B, Maiz-Alonso O, Blanco A, Torre-Salaberri I,
et al. Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients. Journal of Clinical Medicine. 2020; 9(9):2816.
https://doi.org/10.3390/jcm9092816
Chicago/Turabian Style
Sánchez-Bilbao, Lara, David Martínez-López, Marcelino Revenga, Ángel López-Vázquez, Elia Valls-Pascual, Belén Atienza-Mateo, Beatriz Valls-Espinosa, Olga Maiz-Alonso, Ana Blanco, Ignacio Torre-Salaberri,
and et al. 2020. "Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients" Journal of Clinical Medicine 9, no. 9: 2816.
https://doi.org/10.3390/jcm9092816
APA Style
Sánchez-Bilbao, L., Martínez-López, D., Revenga, M., López-Vázquez, Á., Valls-Pascual, E., Atienza-Mateo, B., Valls-Espinosa, B., Maiz-Alonso, O., Blanco, A., Torre-Salaberri, I., Rodríguez-Méndez, V., García-Aparicio, Á., Veroz-González, R., Jovaní, V., Peiteado, D., Sánchez-Orgaz, M., Tomero, E., Toyos-Sáenz de Miera, F. J., Pinillos, V.,
... Blanco, R.
(2020). Anti-IL-6 Receptor Tocilizumab in Refractory Graves’ Orbitopathy: National Multicenter Observational Study of 48 Patients. Journal of Clinical Medicine, 9(9), 2816.
https://doi.org/10.3390/jcm9092816